【摘要】 目的　探讨 C- erb B- 2和 H- ras癌基因在骨巨细胞瘤 (GCT)的表达及与 GCT有关临床指标的关系。方法　应用 SP免疫组织化学方法检测 C- erb B- 2和 H- ras在 5 2例 GCT(GCT按 Jaffe分级 : 级 15例、 级 2 5例、 级 12例 )中的表达。结果　 11例 C- erb B- 2表达阳性 ,阳性率 2 1.2 % ,7例 H- ras表达呈阳性 ,阳性率 13.5 %。其阳性表达与病理分级均无显著性差异 (P >0 .0 5 )。 C- erb B- 2和 H- ras在复发和无复发的病例中 ,阳性表达率分别为 38.5 %、15 .4%和 2 3.1%、10 .3% ,两者同时阳性表达的有 2例。C- erb B- 2和 H- ras的阳性表达与 GCT复发无显著性差异。结论 C- erb B- 2和 H- ras在 GCT中的表达与病理分级和复发无关更多还原

【Abstract】 Objective To investigate the relationship of C erbB 2 and H ras protein overexpression with pathological types and other recurrence. Methods Antibodies against C erbB 2 and p21 H ras proteins were used to measure expression of these proteins in the cells from sections of the giant cell tumor of bone. Results 11 and 7 of 52 tumors expressed C erbB 2 and H ras proteins respectively, but only two cases expressed both C erbB 2 and H ras protein. C erbB 2 and H ras positive cases have no statistical relationship with pathological types and recurrence. Conclustion The expression of C erbB 2 and H ras proteins in the giant cell tumor of bone has no correlation with pathological types and recurrence.更多还原